Shares of Anacor Pharmaceuticals (NASDAQ: ANAC) jumped 26% one day, and 30% the next, with an even bigger catalyst on the horizon. What is driving these explosive share price surges? In the video below, Fool analyst David Williamson discusses one phase 2 trial that has the markets excited, and tells us why the results from its upcoming phase 3 trial for this candidate pipeline drug could be even bigger.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.